Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK

04 Aug 2023
www.pharmaceutical-technology.com
VaccineDrug ApprovalmRNALicense out/inClinical Study
Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK
Preview
Source: Pharmaceutical Technology
The approval for Hipra’s Covid-19 vaccineCovid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech’s mRNA vaccine, Comirnaty. Image Credit: Ansty / Shutterstock.
Accord Healthcare has announced an exclusive commercialisation agreement for a Covid-19 vaccineCovid-19 vaccine manufactured by Spanish biotech Hipra in the UK.
Bimervax is a bivalent recombinant protein vaccine based on alpha and beta variants of SARS-CoV-2.
Recommended Reports
Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - pneumococcal (24-valent) vaccine GlobalData
Accord gears up to commercialise Hipra’s Covid-19 vaccine in the UK
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Herpes Zoster Vaccine in Herpes Zoster (Shingles) GlobalData
View allCompanies IntelligencePfizer IncHera SpAModerna IncBioNTech SENovavax IncView all
It was authorised by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a booster vaccine that provides active immunisation against Covid-19 in people aged 16 years and older on 31 July 2023. It is also authorised for use in the European Union (EU).
However, this marketing agreement comes after a recent EMA decision to seek Covid-19 vaccinesCovid-19 vaccines that specifically target the SARS-CoV-2 XBB 1.5 Omicron subvariant.
Hipra has an existing contract, announced in 2022, with the Health Emergency Preparedness and Response Authority (Hera) of the European Commission (EC) for Bimervax. The agreement allows for the procurement of 250 million doses of the vaccine.
The approval for Hipra’s Covid-19 vaccineCovid-19 vaccine was based on an immunobridging study comparing the efficacy of Bimervax with Pfizer and BioNTech’s mRNA vaccine, Comirnaty.
In the press release, Hipra managing director Carles Fàbrega said: “The Hipra Covid-19 vaccineCovid-19 vaccine is the first human health vaccine to be designed, developed and fully manufactured in Spain.
“Having the structures and capabilities ranging from the most basic research and development to the production of vaccines in the country is a key factor in being able to support a rapid response in the event of future health emergencies and reinforces the strategic autonomy of Europe in the field of health.”
Last month, the European Medicines Agency (EMA) recently granted full approval for Novavax’s Matrix-M adjuvant protein-based Covid-19 vaccine (Nuvaxovid). The vaccine is approved as a primary vaccine for people 12 years of age and older and as a booster dose for adults aged 18 and older.
Moderna has filed for EMA approval for a modified version of its mRNA vaccine based on a SARS-CoV-2 variant.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.